Alkermes Inc patents expiration
1. Aristada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US10226458 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Mar, 2032
(7 years from now) | |
| US9034867 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Nov, 2032
(8 years from now) | |
| US11097006 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(9 years from now) | |
| US9193685 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(9 years from now) | |
| US9452131 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US11406632 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US10238651 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US10813928 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US9526726 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
2. Aristada Initio Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US10688091 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US11154552 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US10849894 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US10016415 | ALKERMES INC | Aripiprazole prodrug compositions |
Sep, 2035
(11 years from now) | |
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT family patents
3. Lybalvi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7956187 | ALKERMES INC | Method for decreasing opioid metabolism |
Oct, 2021
(2 years ago) | |
| US8252929 | ALKERMES INC | 8-carboxamido-2,6-methano-3-benzazocines |
Oct, 2021
(2 years ago) | |
| US7262298 | ALKERMES INC | 4-hydroxybenzomorphans |
Nov, 2025
(1 year, 6 months from now) | |
| US9119848 | ALKERMES INC | Morphinan derivatives for the treatment of drug overdose |
Aug, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11185541 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US10716785 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11351166 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US10300054 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US9517235 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US9126977 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11241425 | ALKERMES INC | Composition for treating mental illness |
Aug, 2031
(7 years from now) | |
| US11793805 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(7 years from now) | |
| US11707466 | ALKERMES INC | Immediate release multilayer tablet |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and sam...
Dosage: TABLET;ORAL
LYBALVI family patents